1-(piperidin-4-yl)pyrrolidine-2,5-dione | 75483-32-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(piperidin-4-yl)pyrrolidine-2,5-dione
• 英文别名: 1-(4-piperidinyl)-pyrrolidine-2,5-dione；1-(4-piperidinyl)-2,5-pyrrolidinedione；1-piperidin-4-ylpyrrolidine-2,5-dione
• CAS: 75483-32-8
• 化学式: C₉H₁₄N₂O₂
• 分子量: 182.222
• InChiKey: YBNKMAJFERLVEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-(piperidin-4-yl)pyrrolidine-2,5-dione 、 吡嗪-2,3-二羧酸 二甲酯 在 甲醇 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 48.0h， 以78%的产率得到5,9-dihydroxy-7-piperidin-4-yl-pyrrolo[3,4-g]quinoxaline-6,8-dione
  参考文献：
  名称：

  Design and Optimization of Tricyclic Phtalimide Analogues as Novel Inhibitors of HIV-1 Integrase

  摘要：

  Human immunodeficiency virus type-1 integrase is an essential enzyme for effective viral replication and hence a valid target for the design of inhibitors. We report here on the design and synthesis of a novel series of phthalimide analogues as integrase inhibitors. The short synthetic pathway enabled us to synthesize a series of analogues with a defined structure diversity. The presence of a single carbonyl-hydroxy-aromatic nitrogen motif was shown to be essential for the enzymatic activity and this was confirmed by molecular docking studies. The enzymatically most active compound from this series is 743,4-dichlorobenzyl)-5,9dihydroxypyrrolo[3,4-g]quinoxaline-6,8-dione (151) with an IC50 value of 112 nM on the HIV-1 integrase enzyme, while ((7-(4-chlorobenzyl)-5,9-dihydroxy-pyrrolo[3,4-g]quinoxaline-6,8-dione (15k)) showed an EC50 of 270 nM against HIV-1 in a cell-based assay.

  DOI：

  10.1021/jm049559q
• 作为产物：
  描述：

  1-(1-benzylpiperidin-4-yl)pyrrolidine-2,5-dione 在 氢氧化钯 氢气 、 甲醇 、 乙酸乙酯 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以to afford 1-(4-piperidinyl)-2,5-pyrrolidinedione, which的产率得到1-(piperidin-4-yl)pyrrolidine-2,5-dione
  参考文献：
  名称：

  Piperidinyl Cyclic Amido Antiviral Agents

  摘要：

  提供的是化合物I式及其药物可接受的盐，它们的药物组合物，它们的制备方法以及它们用于治疗由黄病毒科病毒成员介导的病毒感染，例如丙型肝炎病毒（HCV）的用途。

  公开号：

  US20100272680A1

文献信息

• [EN] SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1<br/>[FR] PYRIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE DNMT1
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017216726A1

  公开（公告）日：2017-12-21

  The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及取代吡啶衍生物。具体而言，该发明涉及符合以下式（Iar）的化合物：（Iar）其中Yar、X1ar、X2ar、R1ar、R2ar、R3ar、R4ar和R5ar如本文所定义；或其药学上可接受的盐或前药。该发明的化合物是DNMT1的选择性抑制剂，可用于治疗癌症、癌前综合征、β血红蛋白病、镰状细胞病、镰状细胞贫血、β地中海贫血以及与DNMT1抑制相关的疾病。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制DNMT1活性和治疗相关疾病的方法。
• Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists: Part 2
  作者：Sanjita Sasmal、D. Balasubrahmanyam、Hariprasada R. Kanna Reddy、Gade Balaji、Gujjary Srinivas、Srisailam Cheera、Chandrasekhar Abbineni、Pradip K. Sasmal、Ish Khanna、V.J. Sebastian、Vikram P. Jadhav、Manvendra P. Singh、Rashmi Talwar、J. Suresh、Dhanya Shashikumar、K. Harinder Reddy、V. Sihorkar、Thomas M. Frimurer、Øystein Rist、Lisbeth Elster、Thomas Högberg

  DOI：10.1016/j.bmcl.2012.03.049

  日期：2012.5

  Melanin concentrating hormone receptor 1 (MCHR1) antagonists have potential for the treatment of obesity and several CNS disorders. In the preceding article, we have described a novel series of quinazolines as MCHR1 antagonists and demonstrated in vivo proof of principle with an early lead. Herein we describe the detailed SAR and SPR studies to identify an optimized lead candidate having good efficacy in

  黑色素浓缩激素受体 1 (MCHR1) 拮抗剂具有治疗肥胖和多种中枢神经系统疾病的潜力。在上一篇文章中，我们描述了一系列新型喹唑啉作为 MCHR1 拮抗剂，并通过早期先导证明了体内原理证明。在此，我们描述了详细的 SAR 和 SPR 研究，以确定在亚慢性 DIO 模型中具有良好疗效且具有良好心血管安全窗口的优化先导候选药物。
• [EN] PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX À BASE DE PIPÉRIDINYLE AMIDO CYCLIQUE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010091411A1

  公开（公告）日：2010-08-12

  Provided are compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

  提供的是式（I）的化合物及其药用盐，它们的药物组合物，它们的制备方法，以及它们用于治疗由黄病毒科病毒介导的病毒感染，如丙型肝炎病毒（HCV）。
• N-Quinazolinylpiperidinyl-lactams
  申请人：Ciba-Geigy Corporation

  公开号：US04255429A1

  公开（公告）日：1981-03-10

  N-[1-(4-amino-2-quinazolinyl)-3- or 4-piperidinyl]-lactams, e.g., those of the formula ##STR1## and salts thereof are antihypertensive agents.

  N-[1-(4-氨基-2-喹唑啉基)-3-或4-哌啶基]-内酰胺，例如，其化学式为##STR1##及其盐是抗高血压药物。
• Piperidinyl-lactams
  申请人：Ciba-Geigy Corporation

  公开号：US04309541A1

  公开（公告）日：1982-01-05

  N-[1-(4-amino-2-quinazolinyl)-3 or 4-piperidinyl]-lactams, e.g., those of the formula ##STR1## and salts thereof are antihypertensive agents.

  N-[1-(4-氨基-2-喹唑啉基)-3或4-哌啶基]-内酰胺，例如公式##STR1##中的化合物及其盐是降压药物。